Development and validation of a peptide-mapping procedure for a novel C1 esterase inhibitor

Peptide mapping is a key method for studying the primary structure of proteins. With its sensitivity to the slightest changes in the covalent structure of a protein, this method is applicable both to medicinal product identification at the control stage and to production process stability monitoring.

The aim of the study was to develop and validate a peptide-mapping procedure for the identification of a novel highly glycosylated recombinant C1 esterase inhibitor.

Materials and methods. The authors studied recombinant human C1 esterase inhibitor products and trypsin. The study involved peptide mapping using reverse-phase high-performance liquid chromatography and high-resolution mass spectrometry. The following statistics were calculated to evaluate the results: mean, standard deviation, and coefficient of variation. The validation parameters included specificity, precision, and robustness.

Results. The authors tested several variants of sample preparation for tryptic digests, including additional N-glycanase treatment and complete deglycosylation, and established the optimal conditions for sample preparation and chromatographic separation of C1 esterase inhibitor peptides to obtain consistent chromatographic profiles (peptide maps). The authors identified characteristic peaks and the corresponding relative retention time and area ranges. The absolute retention time of the second (characteristic) peak was approximately 16.5–16.9 minutes. The relative retention times were 2.14–2.21 for peak 9, 2.55–2.64 for peak 12, 2.97–3.14 for peak 14, 3.11–3.29 for peak 15, and 6.20–6.63 for peak 28.

Conclusions. The authors developed a peptide-mapping procedure for C1 esterase inhibitors and optimised the conditions to achieve an over 18-hour reduction in sample preparation time. This procedure met the established acceptance criteria for specificity, precision, and robustness.

1. Lalonde ME, Durocher Y. Therapeutic glycoprotein production in mammalian cells. J Biotechnol. 2017;251:128–40. https://doi.org/10.1016/j.jbiotec.2017.04.028

2. Qian C, Niu B, Jimenez R, Wang J, Albarghouthi M. Fully automated peptide mapping multi-attribute method by liquid chromatography-mass spectrometry with robotic liquid handling system. J Pharm Biomed Anal. 2021;198:113988. https://doi.org/10.1016/j.jpba.2021.113988

3. Bongers J, Cummings JJ, Ebert MB, Federici MM, Gledhill L, Gulati D, et al. Validation of a peptide mapping method for a therapeutic monoclonal antibody: what could we possibly learn about a method we have run 100 times J Pharm Biomed Anal. 2000;21(6):1099–128. https://doi.org/10.1016/s0731-7085(99)00181-8

4. Mouchahoir T, Schiel JE. Development of an LC-MS/MS peptide mapping protocol for the NISTmAb. Anal Bioanal Chem. 2018;410(8):2111–26. https://doi.org/10.1007/s00216-018-0848-6

5. Allen D, Baffi R, Bausch J, Bongers J, Costello M, Dougherty J Jr, et al. Validation of peptide mapping for protein identity and genetic stability. Biologics and Biotechnology Section, Pharmaceutical Research and Manufacturers of America. Biologicals. 1996;24(3):255–74. https://doi.org/10.1006/biol.1996.0034

6. Andersen N, Vampola L, Jain R, Alvarez M, Chamberlain S, Hilderbrand A, et al. Rapid UHPLC-HRMS peptide mapping for monoclonal antibodies. American Pharmaceutical review. 2014.

7. Xu CF, Wang Y, Bryngelson P, Sosic Z, Zang L. Sequence variant and posttranslational modification analysis during cell line selection via high-throughput peptide mapping. Adv Exp Med Biol. 2019;1140:225–36. https://doi.org/10.1007/978-3-030-15950-4_12

8. Beinrohr L, Harmat V, Dobó J, Loörincz Z, Gál P, Závodszky P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem. 2007;282(29):21100–9. https://doi.org/10.1074/jbc.M700841200

9. Keating GM. Human C1-esterase inhibitor concentrate (Berinert). BioDrugs. 2009;23(6):399–406. https://doi.org/10.2165/11201100-000000000-00000

10. Ruddy S, Manning MC, Holcomb RE. C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency. Patent of the USA US9616111B2; 2015.

11. Stavenhagen K, Kayili HM, Holst S, Koeleman CAM, Engel R, Wouters D, et al. N- and O-glycosylation analysis of human C1-inhibitor reveals extensive mucin-type O-glycosylation. Mol Cell Proteomics. 2018;17(6):1225–38. https://doi.org/10.1074/mcp.RA117.000240

12. Ustinnikova OB, Volkova RA, Movsesyants AA, Merkulov VA, Bondarev VP. Recommendations on the certification of reference standards for structure identification of recombinant therapeutic proteins. Biological Products. Prevention, Diagnosis, Treatment. 2022;22(2):218–25 (In Russ.). https://doi.org/10.30895/2221-996X-2022-22-2-218-225

13. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7. https://doi.org/10.1016/0003-9861(59)90090-6

14. Riener CK, Kada G, Gruber HJ. Quick measurement of protein sulfhydryls with Ellman’s reagent and with 4,4’-dithiodipyridine. Anal Bioanal Chem. 2002;373(4–5):266–76. https://doi.org/10.1007/s00216-002-1347-2

15. Winther JR, Thorpe C. Quantification of thiols and disulfides. Biochim Biophys Acta. 2014;1840(2):838–46. https://doi.org/10.1016/j.bbagen.2013.03.031

16. Zubareva E, Degterev M, Kazarov A, Zhiliaeva M, Ulyanova K, Simonov V, et al. Physicochemical and biological characterization of rhC1INH expressed in CHO cells. Pharmaceuticals (Basel). 2021;14(11):1180. https://doi.org/10.3390/ph14111180

17. Goloshchapova EO, Minero AS, Rounova OB, Ustinnikova OB. Development of a peptide mapping technique to evaluate the authenticity of recombinant interferon beta-1b. Russian Journal of Biopharmaceuticals. 2021;13(1):21–6 (In Russ.). https://doi.org/10.30906/2073-8099-2021-13-1-21-26

18. Ustinnikova OB, Goloshchapova EO, Runova OB, Korotkov MG, Volkova RA. Development of a qualification procedure for methionine form of interferon alfa-2b standard to confirm its authenticity by means of a peptide mapping method. Medical Immunology (Russia). 2018;20(4):543–50 (In Russ.). https://doi.org/10.15789/1563-0625-2018-4-543-550